Core Viewpoint - The company has implemented a "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on enhancing operational efficiency, strengthening market competitiveness, and safeguarding investor interests. Group 1: Company Overview - The company is focused on the human vaccine sector, particularly influenza vaccines, and has developed a product line covering ten vaccines for five infectious diseases [4][5]. - The company has a strong commitment to maintaining high safety and efficacy standards for its products, with its quadrivalent influenza vaccine exceeding national and European pharmacopoeia standards [4]. Group 2: Financial Data - The company reported a total R&D investment of 23.85 million yuan in the first half of 2025, reflecting a year-on-year increase of 15.25% [8]. - The company has effectively managed its costs, resulting in a decrease in management expenses compared to the previous year [12]. Group 3: Operational Highlights - The company has accelerated the production and approval process for its quadrivalent influenza vaccine, aiming to increase market share by improving production efficiency [6][7]. - The company has established a marketing network covering over 2,000 disease control centers across 30 provinces, enhancing customer service and exploring new sales channels [10]. Group 4: R&D and Innovation - The company is actively pursuing R&D in various vaccine areas, including rabies, chickenpox, and pneumonia, with several projects progressing through clinical trials [8]. - The company has initiated the III phase clinical trial for its quadrivalent influenza vaccine for children, demonstrating its commitment to innovation [8]. Group 5: Governance and Compliance - The company has strengthened its governance structure, ensuring compliance with regulatory requirements and enhancing decision-making efficiency through various board committees [13][20]. - The company has conducted multiple board meetings and shareholder meetings to ensure transparency and effective governance [14][19]. Group 6: Investor Relations - The company emphasizes investor communication, planning to hold a performance briefing to address investor concerns and enhance transparency [26][27]. - The company has established a mechanism for timely responses to investor inquiries, ensuring that information is accurate and complete [18][19]. Group 7: Fund Management - The company has raised 1.21396 billion yuan through its public offering, with net proceeds of 1.13567 billion yuan after deducting issuance costs [35][36]. - As of June 30, 2025, the company had a balance of 119.05 million yuan in unutilized raised funds, demonstrating effective fund management [37]. Group 8: Future Outlook - The company plans to continue enhancing its R&D efforts and operational efficiency in the second half of 2025, aiming to strengthen its market position and investor returns [9][23].

Meeting Overview - The second meeting of the Supervisory Board of Jiangsu Jindike Biotechnology Co., Ltd. was held on August 21, 2025, combining in-person and remote participation, with all three supervisors present for voting [1]. Resolutions Passed - The Supervisory Board unanimously approved the 2025 Half-Year Report and its summary, confirming that the report's preparation and review complied with relevant laws and internal regulations, and accurately reflected the company's operational and financial status for the first half of 2025 [1][2]. - The Supervisory Board also approved the Special Report on the Storage and Actual Use of Raised Funds for the first half of 2025, affirming that the use of raised funds adhered to regulatory requirements and did not harm the interests of the company or its shareholders [2][3].

Group 1 - The company reported a revenue of 3.5242 million yuan for the first half of 2025, representing a year-on-year growth of 7.18% [1] - The net loss attributable to shareholders of the listed company was 39.6531 million yuan, with a net loss of 42.9408 million yuan after deducting non-recurring gains and losses [1] - The basic loss per share was 0.32 yuan [1]

Core Viewpoint - Jindike (688670) reported a revenue of 3.5242 million yuan for the first half of 2025, reflecting a year-on-year growth of 7.18%, but recorded a net loss attributable to shareholders of 39.6531 million yuan, with a basic earnings per share of -0.32 yuan [1] Financial Performance - The company achieved an operating revenue of 3.5242 million yuan in the first half of 2025 [1] - Year-on-year revenue growth was 7.18% [1] - The net profit attributable to shareholders was -39.6531 million yuan [1] - Basic earnings per share stood at -0.32 yuan [1]

证券代码：688670 证券简称：金迪克 公告编号：2025-023 江苏金迪克生物技术股份有限公司 关于 2025 年"提质增效重回报"专项行动方案的 半年度评估报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 报告期内，公司持续提升经营质量，在疫苗生产、批签发、研发、销售、经 营管理等方面实现成果如下： 1、加快四价流感疫苗生产与批签发进度，提高市场份额 2025 年 2 月底，WHO 召开专家会议宣布 2025-2026 年度北半球流感疫苗推 荐毒株组分，公司根据推荐毒株组织安排生产。本年度公司提前排产，加强设备 维护维修与车间环境保持，加强各部门协调配合，进一步提高生产效率。 公司目前可商业化生产的流感疫苗车间只有一条原液生产线，四种流感病毒 1 亚型原液的生产只有在依次完成后，才能进行制剂的配制、灌装和包装，生产周 期比有多条原液生产线的流感疫苗企业长。公司在建的四价流感病毒裂解疫苗车 间年设计产能为 3000 万支，新车间建成后，不仅可以提升产能，更可缩短生产 周期，有助于公司未来加快流感疫苗产品上市销售， ...

江苏金迪克生物技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688670 证券简称：金迪克 公告编号：2025-022 重要内容提示： 会议召开时间：2025 年 9 月 3 日（星期三）13:00-14:00 会议召开地点：上海证券交易所"上证路演中心"网络平台（网址： http://roadshow.sseinfo.com/） 会议召开方式：图文显示（可选）+网络文字互动方式 投资者可于 2025 年 9 月 2 日（星期二）17:00 前将有关问题通过电子邮 件、传真的形式发送至公司邮箱 gdk001@gdkbio.com。公司将在业绩说明会上 对投资者普遍关注的问题进行回答。 江苏金迪克生物技术股份有限公司（以下简称"公司"）将于 2025 年 8 月 22 日在《上海证券报》《中国证券报》《证券时报》《证券日报》及上海证券交 易所网站（www.sse.com.cn）披露《江苏金迪克生物技术股份有限公司 2025 年 半年度报告》及《江苏金 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-021 具体情况如下： 单位：万元 | 项目 | 金额 | | --- | --- | | 募集资金总额 | 121,396.00 | | 减：券商承销佣金及保荐费 | 6,349.19 | | 收到募集资金总额 | 115,046.81 | | 减：以募集资金置换预先投入自筹资金的金额 | 14,596.29 | | 减：以募集资金置换预先支付发行费用的金额 | 342.30 | | 减：支付不含税发行费用的金额 | 1,136.90 | | 减：直接投入募集项目的金额 | 88,846.20 | | 减：购买理财产品、定期存款及结构性存款余额 | 5,500.00 | 1 经中国证券监督管理委员会证监许可[2021]1877 号文核准，并经上海证券交 易所同意，本公司由主承销商中信证券股份有限公司于 2021 年 7 月 21 日向社会 公众公开发行普通股（A 股）股票 2,200.00 万股，每股面值 1.00 元，每股发行 价人民币 55.18 元。截至 2021 年 7 月 27 日止，本公司共募集资金 1,213,960,000.00 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-020 江苏金迪克生物技术股份有限公司 经审议，监事会认为公司 2025 年半年度报告及其摘要的编制和审议程序符 合相关法律法规及《公司章程》等内部规章制度的规定；公司 2025 年半年度报 告的内容和格式符合中国证监会和上海证券交易所的规定，所包含的信息能从 各个方面真实反映出公司 2025 年上半年度的经营管理和财务状况等事项；半年 度报告编制过程中，未发现公司参与半年度报告编制和审议的人员有违反保密 规定的行为；监事会全体成员保证公司 2025 年半年度报告披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或重大遗漏，并对其内容真实性、 准确性和完整性依法承担法律责任。全体监事一致同意通过该报告。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《江苏金迪克生物技术股份有限公司 2025 年半年度报告》和《江苏金迪克生物 技术股份有限公司 2025 年半年度报告摘要》。 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不 ...

Core Viewpoint - The company, Jindike (688670.SH), reported a revenue increase of 7.18% year-on-year, but still faced a net loss, indicating challenges in profitability despite revenue growth [1] Financial Performance - The company achieved an operating revenue of 3.5242 million yuan, reflecting a year-on-year increase of 7.18% [1] - The net profit attributable to the parent company was -39.6531 million yuan, showing a year-on-year reduction in losses by 2.97% [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -42.9408 million yuan, with a year-on-year reduction in losses of 8.92% [1] Market Opportunity - The domestic penetration rate of quadrivalent influenza vaccines is significantly lower than that of foreign markets, indicating substantial growth potential [1] - The company aims to capitalize on the steady growth of the influenza vaccine market in China by ensuring product quality and actively pursuing sales transformation [1] - The sales strategy focuses on deepening market penetration, enhancing service to end users, and expanding the incremental market to increase market share in the influenza vaccine sector [1]

江苏金迪克生物技术股份有限公司2025 年半年度报告 公司代码：688670 公司简称：金迪克 江苏金迪克生物技术股份有限公司 2025 年半年度报告 1/166 江苏金迪克生物技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 五、 公司负责人余军、主管会计工作负责人黄强及会计机构负责人（会计主管人员）黄强声明： 保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险，敬请查阅本报告第三节 "管理层讨论与分析"中"风险因素"的相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及公司未来计划，发展战略等前瞻性描述，不构成对投资者的实质承诺，敬请投 资者注意投资风险。 ...